ProCE Banner Activity

Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

Podcast Episodes

In this podcast episode, listen to Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, discuss key updates and new clinical trial data for gynecologic cancers presented at the 2023 ASCO Annual Meeting, including final overall survival data from KEYNOTE-826; a study from the Canadian Cancer Trials Network on radical vs simple  hysterectomy in locally advanced, recurrent cervical cancers; and new data for novel combinations of immunotherapy plus PARP inhibitors in ovarian and endometrial cancer.

Released: June 22, 2023

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD

Associate Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Kathleen Moore

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Virginia kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase 1 Clinical Trials Unit
Professor
Department of Gynecologic Oncology
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Disclosure

Primary Author

Nicoletta Colombo, MD

Associate Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Immunogen Merck Sharp & Doheme, Mersana, Nuvation, Oncxerna, Pfizer, Pieris, Roche.

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Virginia kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase 1 Clinical Trials Unit
Professor
Department of Gynecologic Oncology
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma

Kathleen Moore, MD: consultant/advisor/speaker: Aadi, Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Caris, Clovis, Eisai, Genentech/Roche, GlaxoSmithKline, Hengrui, Immunogen, Lilly, Mereo, Merck, Mersana, Myriad, Novartis, Onconova, OncXerna, Panavance, VBL Therapeutics, Verastem.